Paper Details

  1. Home
  2. Paper Details

Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.

Author: SomaiahNeeta, SymcoxMarina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
CommentA short article/note that provides an opinion/perspective/interpretation on a published paper/topic.

Overview

The INVICTUS study evaluated the efficacy and safety of ripretinib in patients with advanced gastrointestinal stromal tumor (GIST) who had received at least three prior tyrosine kinase inhibitor treatments. The results showed that ripretinib significantly increased the length of time participants survived before their cancer worsened. However, ripretinib was associated with side effects of varying severity. Based on these findings, ripretinib was approved as a treatment option for adults with advanced GIST who have previously been treated with three or more tyrosine kinase inhibitors.
Paper Details　
Original Abstract of the Article :
The purpose of this summary is to help you understand the results of the INVICTUS study originally published in the journal <i>Lancet Oncology</i>. INVICTUS is a clinical study which looked at ripretinib as a potential treatment for advanced gastrointestinal stromal tumor, also known as GIST. GIST i...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2217/fon-2021-0803

データ提供：米国国立医学図書館（NLM）

Ripretinib for Advanced GIST: A New Oasis in the Desert of Treatment Options

The treatment of [advanced gastrointestinal stromal tumor (GIST)] presents a significant challenge for [oncologists]. This study, known as the [INVICTUS Trial], evaluated the efficacy and safety of [ripretinib] as a treatment option for [advanced GIST] in patients who have previously received [three or more lines] of [tyrosine kinase inhibitors (TKIs)]. The researchers compared the effectiveness of [ripretinib] to [placebo].

A New Oasis: Ripretinib for Advanced GIST

The study demonstrated that [ripretinib] significantly increased the [length of time] patients survived before their [cancer] worsened. This finding offers a promising new treatment option for [advanced GIST] patients who have exhausted other therapeutic options. However, the researchers also noted that [ripretinib] was associated with [side effects] of varying severity.

Navigating the Desert of GIST: Finding Effective Treatments

This research highlights the importance of developing new [therapeutic approaches] for [advanced GIST]. The effectiveness of [ripretinib] offers a beacon of hope for patients who have limited treatment options. This study underscores the need for continued research to identify [safe and effective treatments] for [GIST], ultimately improving the quality of life and survival for patients with this challenging disease.

Dr.Camel's Conclusion

The desert of [GIST] can be a daunting place, but this study offers a new oasis in the form of [ripretinib]. While further research is needed to optimize its use, this promising new treatment holds the potential to improve outcomes for patients with [advanced GIST] who have limited treatment options.

Date :
  1. Date Completed 2021-12-03
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

34661454

DOI: Digital Object Identifier

10.2217/fon-2021-0803

Related Literature

Article Analysis
・Side Effects of ripretinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.